Navigation Links
Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
Date:10/29/2007

this disease.

About Coley Pharmaceutical Group

Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi- aventis, GlaxoSmithKline, Merck, Novartis and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.

Safe Harbor Statement

Certain statements in this news release concerning Coley's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the safety and tolerability of CPG 52364 for the treatment of Systemic Lupus Erythematosus (SLE); confirmation of TLR7/8/9 as a target for SLE; ; Coley's ability to enroll subjects in a Phase I clinical trial of CPG 52364; and, the timing of results of a Phase I clinical trial with CPG 52364. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Coley might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; uncertainties as to the future success of ongoing and planned clinical trials; the risk that results from early stage clinical trials may not be indicative of results in later stage trials; the unp
'/>"/>

SOURCE Coley Pharmaceutical Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... 16 American pharmaceutical manufacturer Alpharma Inc. ... resolve False Claims Act allegations in connection with the ... announced today. The settlement resolves allegations that, between ... , Alpharma paid health care providers to induce them ... the safety and efficacy of the drug, which is ...
(Date:3/16/2010)... , March 16 New research ... in new medicines and vaccines by the U.S. biopharmaceutical ... increase of more than $1.5 billion from ... a combined analysis conducted by Burrill & Company, a ... whose principal activities are in Private Equity, Venture Capital, ...
(Date:3/16/2010)... -- BioVigil LLC has released the second generation of the BioVigil hand hygiene monitoring system. The innovative system enables hospitals to more effectively combat Hospital-Acquired ... ... , ... ... ...
Breaking Medicine Technology:Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 3R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds 2R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds 3R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds 4BioVigil Releases Second-Generation Hand Hygiene Monitoring System 2BioVigil Releases Second-Generation Hand Hygiene Monitoring System 3BioVigil Releases Second-Generation Hand Hygiene Monitoring System 4American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China 13124 1American Oriental Bioengineering Honorably Elected a Top 20 Most Competitive Public Pharmaceutical Company in China 13124 2Weight Watchers Announces Second Quarter 2009 Earnings Conference Call 52240 1Weight Watchers Announces Second Quarter 2009 Earnings Conference Call 52240 2Ortho Clinical Diagnostics Launches 24 Hour Remote Monitoring Center 52238 1Ortho Clinical Diagnostics Launches 24 Hour Remote Monitoring Center 52238 2Ortho Clinical Diagnostics Launches 24 Hour Remote Monitoring Center 52238 3Ortho Clinical Diagnostics Launches 24 Hour Remote Monitoring Center 52238 4
... On February 13, the NYC Department of,Health "unveiled a brand ... media campaign to encourage New Yorker,s to ,get some.," The,Release ... at,"busy crossroads," that the campaign would include ads on TV ... and that over 36 million,condoms were given out last year., ...
... Feb. 19 A natural health company located ... results of,recent clinical studies indicating their oxygen colon ... and Irritable Bowel,Syndrome. In fact, the scientific data ... 85% MORE EFFECTIVE AT ELIMINATING SYMPTOMS,THAN TRADITIONAL LAXATIVES ...
Other Medicine Technology:NYC Department of Health's 'Get Some NYC Condoms' Sends Wrong Message and Misuses Tax Dollars, says MIM President Bob Peters 2Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies 2
(Date:3/16/2010)... Robert Myers , the company,s President, will present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24, 2010 at ... ... , ... ... ...
(Date:3/16/2010)... March 16 TeamHealth Holdings, Inc. ("TeamHealth") ... suppliers of outsourced healthcare professional staffing and administrative services ... United States , today announced that its management will ... Conference on March 24, 2010 , at the ... begin at 9:30 AM Eastern time .  Interested ...
(Date:3/16/2010)... GLEN ALLEN, Va. , March 16 ... report on Form 10-K today with the Securities and Exchange ... for 2009 compared to $0.5 million in ... at year-end 2009 totaled $12.4 million compared with ... for 2009 totaled approximately $(22.8) million compared to ...
(Date:3/16/2010)... March 16, 2010 The AIUM is ... have collaborated with AIUM to endorse the ... of Musculoskeletal Ultrasound Examinations. The guidelines allow ... physicians, podiatrists, and sonographers, to perform musculoskeletal ... future of this growing field. , ...
(Date:3/16/2010)... Newspaper, magazine stories shy away from negative side ... March 16 (HealthDay News) -- People often complain ... when it comes to cancer most newspaper and ... suggest. , The study authors found that articles ... survival, with far less attention given to cancer ...
Breaking Medicine News(10 mins):Health News:Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 2Health News:TeamHealth Holdings, Inc., to Present at Barclays Capital Global Healthcare Conference 3Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 2Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 3Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 4Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 5Health News:Star Scientific Files Annual Financial Report With SEC, Regains Compliance With NASDAQ Minimum Bid-Price Requirement 6Health News:Unprecedented AIUM training guidelines speak to future of musculoskeletal ultrasound 2Health News:Cancer Articles Tend to Focus on Positive Outcomes 2
... Washington, D.C., and Meet with Elected Officials, WASHINGTON, ... to Washington, D.C., this April 1 to meet with,congressional ... with Disabilities Act, support for epilepsy public health,programs and ... is one of 50 young people with epilepsy participating ...
... Washington, D.C., and Meet with Elected,Officials, WASHINGTON, March ... Washington, D.C., this April 1 to meet,with congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... and Meet With Elected,Officials, WASHINGTON, March 14 ... this April 1 to meet with,congressional leaders and gain ... support for epilepsy public health,programs and more research toward ... of 50 young people with epilepsy participating in,Kids Speak ...
... Corporation,(NYSE: STE ) today announced that Michael ... president and chief financial officer. Mr. Tokich joined,STERIS ... and corporate,controller. He will report to Walt Rosebrough, ... for financial reporting,financial planning, investor relations, tax, and ...
... High-Fiber Line to its Selection ... of All-Natural Cookies, ... its new line of "Nana,s Fiber Cookie Bars." The,new high-fiber cookie ... cookie. The new Fiber Bar will complement the company,s,existing lines of ...
... aggressive disease and lower survival rates if they are ... March 15 issue of Clinical Cancer Research, a journal ... The more obese a patient is, the more aggressive ... medicine in the Department of Breast Medical Oncology at ...
Other Medicine News:Health News:Florida Youth Named National Epilepsy Spokesperson 2Health News:Vermont Youth Named National Epilepsy Spokesperson 2Health News:Tennessee Youth Named National Epilepsy Spokesperson 2Health News:STERIS Corporation Names Michael J. Tokich Chief Financial Officer 2Health News:STERIS Corporation Names Michael J. Tokich Chief Financial Officer 3Health News:STERIS Corporation Names Michael J. Tokich Chief Financial Officer 4Health News:Have Your Cookie and Fiber too With Nana's Newest Cookie Bar 2Health News:Breast cancer more aggressive among obese women 2
... the Vortex Vacuum Mixer is clinically proven to ... traditional vacuum mixers. The ergonomically angled base means ... crank three revolutions every time you turn ... stirring, cutting down on the amount of air ...
This high technology cast plaster cutter saw is very easy and comfortable to use....
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
The Orengo staple is an oval staple, with thicker and longer legs (25 mm). It is then more especially bound to be used onto thick bones. The design of its stapler makes it more difficult to use und...
Medicine Products: